Last reviewed · How we verify
Ritonavir boosted Atazanavir + 2 NRTIs
Atazanavir inhibits HIV protease to prevent viral replication, while ritonavir boosts its blood levels, and the two NRTIs block reverse transcriptase to further suppress HIV.
Atazanavir inhibits HIV protease to prevent viral replication, while ritonavir boosts its blood levels, and the two NRTIs block reverse transcriptase to further suppress HIV. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.
At a glance
| Generic name | Ritonavir boosted Atazanavir + 2 NRTIs |
|---|---|
| Sponsor | Fundacion SEIMC-GESIDA |
| Drug class | Protease inhibitor combination antiretroviral therapy |
| Target | HIV protease, HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Atazanavir is a protease inhibitor that blocks the HIV protease enzyme, preventing the maturation of infectious viral particles. Ritonavir is a pharmacokinetic booster that inhibits cytochrome P450 metabolism, increasing atazanavir concentrations and allowing for lower, more convenient dosing. The two nucleoside reverse transcriptase inhibitors (NRTIs) work synergistically by blocking reverse transcriptase, the enzyme HIV uses to convert its RNA genome into DNA.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients
Common side effects
- Hyperbilirubinemia
- Nausea
- Diarrhea
- Headache
- Rash
- Abdominal pain
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) (PHASE3)
- Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults (PHASE4)
- Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients (PHASE4)
- HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen (PHASE4)
- Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF (PHASE3)
- Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ritonavir boosted Atazanavir + 2 NRTIs CI brief — competitive landscape report
- Ritonavir boosted Atazanavir + 2 NRTIs updates RSS · CI watch RSS
- Fundacion SEIMC-GESIDA portfolio CI